Vaxart Total Debt To Capitalization from 2010 to 2024

VXRT Stock  USD 0.61  0.01  1.67%   
Vaxart Total Debt To Capitalization yearly trend continues to be comparatively stable with very little volatility. Total Debt To Capitalization will likely drop to 0.1 in 2024. From the period from 2010 to 2024, Vaxart Total Debt To Capitalization quarterly data regression had r-value of  0 and coefficient of variation of  377.98. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.10004515
Current Value
0.095
Quarterly Volatility
6.79050371
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxart financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxart's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 M, Interest Expense of 1.4 M or Total Revenue of 7 M, as well as many indicators such as Price To Sales Ratio of 10.68, Dividend Yield of 0.0 or PTB Ratio of 2.34. Vaxart financial statements analysis is a perfect complement when working with Vaxart Valuation or Volatility modules.
  
Check out the analysis of Vaxart Correlation against competitors.

Latest Vaxart's Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Vaxart Inc over the last few years. It is Vaxart's Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxart's overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Very volatile
   Total Debt To Capitalization   
       Timeline  

Vaxart Total Debt To Capitalization Regression Statistics

Arithmetic Mean1.80
Geometric Mean0.02
Coefficient Of Variation377.98
Mean Deviation3.27
Median0.01
Standard Deviation6.79
Sample Variance46.11
Range26.3408
R-Value0
Mean Square Error49.66
R-Squared0.00000254
Significance1.00
Slope0
Total Sum of Squares645.55

Vaxart Total Debt To Capitalization History

2024 0.095
2023 0.1
2019 8.58E-4
2018 0.24
2017 26.34
2016 0.0158
2015 0.0149

About Vaxart Financial Statements

Vaxart shareholders use historical fundamental indicators, such as Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although Vaxart investors may analyze each financial statement separately, they are all interrelated. The changes in Vaxart's assets and liabilities, for example, are also reflected in the revenues and expenses on on Vaxart's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Debt To Capitalization 0.10  0.10 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.